Galapagos

Gilead and Kites exhibit booth at ASH 2025
Biotech

Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos

Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
James Waldron Mar 24, 2026 3:34am
Euros cash money

Galapagos took €228M hit from cell therapy wind-down

Feb 24, 2026 6:30am
Comedy and tragedy masks on red curtain background

Galapagos' last immunology asset posts mixed results

Dec 19, 2025 6:05am
Rotten tomato splat fruit

Fierce Biotech's Rotten Tomatoes of 2025

Dec 16, 2025 4:30am
plan B fail reroute road path trail miss

'Gilead wants us to rebuild': Why Galapagos can't go extinct

Nov 19, 2025 7:50am
End of road sign on street

Galapagos to wind down cell therapy unit, threatening 365 jobs

Oct 21, 2025 9:30am